Long-term metabolic and inflammatory effects of second-generation antipsychotics: A study in mentally disordered offenders
More details
Hide details
Department of Nutritional Sciences and Dietetics, School of Health Sciences, International Hellenic University, Thessaloniki, Greece
1st Department of Psychiatry, Sector of Neurosciences and Sensory Organs, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
Department of Forensic Psychiatry, Psychiatric Hospital of Thessaloniki, Thessaloniki, Greece
Psychiatric Clinic, General University Hospital of Larissa, Larissa, Greece
Department of Practical Abilities-Human Sciences, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
Publication date: 2022-05-27
Corresponding author
Emilia Vassilopoulou   

Department of Nutritional Sciences and Dietetics, School of Health Sciences, International Hellenic University, GR-57400, Sindos, Thessaloniki, Greece
Public Health Toxicol 2022;2(Supplement Supplement 1):A99
This paper combines forensic psychiatry, antipsychotics drug and metabolic disturbances. It refers to mentally disordered offenders provided with forensic psychiatric care are often treated with second generation antipsychotic medication and experience metabolic and inflammatory side effects. Three-year variability of selected anthropometric, biochemical and inflammatory markers was monitored in forensic psychiatric patients receiving antipsychotic (AP) medication for more than five years, according to the type of ΑP. Thirty-five patients with psychotic disorders were classified into two groups based on the type of AP. Specifically: AP1, related to a lower risk, and AP2, related to an increased risk of weight gain and metabolic complications. Biochemical, hematological, anthropometric, blood pressure, and medication data were retrieved from the individual medical files. No significant differences in weight and glucose and cholesterol levels were observed, but patients taking AP2 more often needed drugs to control diabetes mellitus, lipidemia, and cardiovascular disease. In those taking AP1, the mean HDL level decreased significantly over time (p < 0.05) and a higher proportion developed higher blood pressure (52.9% of AP1 vs. 16.7% AP2). In the AP2 group the median level of C-reactive protein (p < 0.001) and the white blood cell count increased over the three years (p < 0.001).
Abdel-Wahab BA, Metwally ME. Clozapine-Induced Cardiotoxicity: Role of Oxidative Stress, Tumour Necrosis Factor Alpha and NF-κβ. Cardiovasc Toxicol. 2015;15(4):355-365. doi:10.1007/s12012-014-9304-9
Al-Daghri NM, Rahman S, Sabico S, et al. Association of Vitamin B12 with Pro-Inflammatory Cytokines and Biochemical Markers Related to Cardiometabolic Risk in Saudi Subjects. Nutrients. 2016;8(9):460. doi:10.3390/nu8090460
Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003;64(5):598-604. doi:10.4088/jcp.v64n0516
Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014;9(4):e94112. doi:10.1371/journal.pone.0094112
Barton BB, Segger F, Fischer K, Obermeier M, Musil R. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(3):295-314. doi:10.1080/14740338.2020.1713091
Brietzke E, Mansur RB, Subramaniapillai M, et al. Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments. Neurosci Biobehav Rev. 2018;94:11-16. doi:10.1016/j.neubiorev.2018.07.020
Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-1773. doi:10.1001/jama.2009.1549
Correll CU, Joffe BI, Rosen LM, Sullivan TB, Joffe RT. Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry. 2015;14(1):56-63. doi:10.1002/wps.20187
Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17(2):97-107. doi:10.1016/j.molmed.2010.10.010
Correll CU, Robinson DG, Schooler NR, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry. 2014;71(12):1350-1363. doi:10.1001/jamapsychiatry.2014.1314
De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114-126. doi:10.1038/nrendo.2011.156
Farrer S. Beyond Statins: Emerging Evidence for HDL-Increasing Therapies and Diet in Treating Cardiovascular Disease. Adv Prev Med. 2018;(6024747):1-8. doi:10.1155/2018/6024747
Fernandes BS, Steiner J, Bernstein HG, et al. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol Psychiatry. 2016;21(4):554-564. doi:10.1038/mp.2015.87
Firth J, Veronese N, Cotter J, et al. What Is the Role of Dietary Inflammation in Severe Mental Illness? A Review of Observational and Experimental Findings. Front Psychiatry. 2019;10:350. doi:10.3389/fpsyt.2019.00350
Hasnain M, Vieweg WV, Hollett B. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgrad Med. 2012;124(4):154-167. doi:10.3810/pgm.2012.07.2577
Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62(1):19-28. doi:10.1001/archpsyc.62.1.19
Howell S, Yarovova E, Khwanda A, Rosen SD. Cardiovascular effects of psychotic illnesses and antipsychotic therapy. Heart. 2019;105(24):1852-1859. doi:10.1136/heartjnl-2017-312107
Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097. doi:10.1016/S0140-6736(08)60486-9
Kang SH, Lee JI. Metabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychotics. Psychiatry Investig. 2015;12(2):242-248. doi:10.4306/pi.2015.12.2.242
Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009;(4):CD006627. doi:10.1002/14651858.CD006627.pub2
Leistedt S, Bongaerts X, Macquet D. Forensic psychiatry in Belgium in 2021: An overview of the current situation. Forensic Sci Int Mind Law. 2021;2:100047. doi:10.1016/j.fsiml.2021.100047
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. doi:10.1056/NEJMoa051688
Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry. 2000;61(10):742-749. doi:10.4088/jcp.v61n1006
Musil R, Obermeier M, Russ P, Hamerle M. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf. 2015;14(1):73-96. doi:10.1517/14740338.2015.974549
Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13(1):27-35. doi:10.1038/
Nikolić-Kokić A, Tatalović N, Nestorov J, et al. Clozapine, ziprasidone, and sertindole-induced morphological changes in the rat heart and their relationship to antioxidant enzymes function. J Toxicol Environ Health A. 2018;81(17):844-853. doi:10.1080/15287394.2018.1495587
Pillinger T, Osimo EF, de Marvao A, et al. Cardiac structure and function in patients with schizophrenia taking antipsychotic drugs: an MRI study. Transl Psychiatry. 2019;9(1):163. doi:10.1038/s41398-019-0502-x
Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233. doi:10.1016/j.schres.2010.07.012
Saedisomeolia A, Djalali M, Moghadam AM, Ramezankhani O, Najmi L. Folate and vitamin B12 status in schizophrenic patients. J Res Med Sci. 2011;16(Suppl 1):S437-S441. Accessed May 1, 2022.
Salvi V, Barone-Adesi F, D'Ambrosio V, Albert U, Maina G. High H1-affinity antidepressants and risk of metabolic syndrome in bipolar disorder. Psychopharmacology (Berl). 2016;233(1):49-56. doi:10.1007/s00213-015-4085-9
Schulte PF, Bocxe JT, Doodeman HJ, van Haelst IM, Cohen D. Risk of New-Onset Diabetes After Long-Term Treatment With Clozapine in Comparison to Other Antipsychotics in Patients With Schizophrenia. J Clin Psychopharmacol. 2016;36(2):115-119. doi:10.1097/JCP.0000000000000465
Scigliano G, Ronchetti G. Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis. CNS Drugs. 2013;27(4):249-257. doi:10.1007/s40263-013-0054-1
Shrivastava A, Johnston ME. Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management. Mens Sana Monogr. 2010;8(1):53-68. doi:10.4103/0973-1229.58819
Siafis S, Tzachanis D, Samara M, Papazisis G. Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. Curr Neuropharmacol. 2018;16(8):1210-1223. doi:10.2174/1570159X15666170630163616
Spertus J, Horvitz-Lennon M, Abing H, Normand SL. Risk of weight gain for specific antipsychotic drugs: a meta-analysis. NPJ Schizophr. 2018;4(1):12. doi:10.1038/s41537-018-0053-9
Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163(4):611-622. doi:10.1176/appi.ajp.163.4.611
Takeuchi Y, Kajiyama K, Ishiguro C, Uyama Y. Atypical Antipsychotics and the Risk of Hyperlipidemia: A Sequence Symmetry Analysis. Drug Saf. 2015;38(7):641-650. doi:10.1007/s40264-015-0298-4
Tătaru N, Marinov P, Douzenis A, Novotni A, Kecman B. Forensic psychiatry in some Balkan countries. Curr Opin Psychiatry. 2010;23(5):472-480. doi:10.1097/YCO.0b013e32833cfc05
Tenback DE, van Kessel F, Jessurun J, Pijl YJ, Heerdink ER, van Harten PN. Risicofactoren voor inactiviteit bij patiënten met ernstige psychiatrische aandoeningen in de langdurige zorg. Risk factors for inactivity in patients in long-term care with severe mental illness. Article in Dutch, Tijdschr Psychiatr. 2013;55(2):83-91. Accessed May 1, 2022. http://www.tijdschriftvoorpsyc...
Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14(3):339-347. doi:10.1002/wps.20252
Vázquez-Bourgon J, Pérez-Iglesias R, Ortiz-García de la Foz V, Suárez Pinilla P, Díaz Martínez Á, Crespo-Facorro B. Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis. Psychopharmacology (Berl). 2018;235(1):245-255. doi:10.1007/s00213-017-4763-x
Whicher CA, Price HC, Holt RIG. Mechanisms in endocrinology: Antipsychotic medication and type 2 diabetes and impaired glucose regulation. Eur J Endocrinol. 2018;178(6):R245-R258. doi:10.1530/EJE-18-0022
Yan H, Chen JD, Zheng XY. Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia. Psychopharmacology (Berl). 2013;229(1):1-7. doi:10.1007/s00213-013-3193-7
Zhang JP, Lencz T, Zhang RX, et al. Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis. Schizophr Bull. 2016;42(6):1418-1437. doi:10.1093/schbul/sbw058
Journals System - logo
Scroll to top